Recently, three punishment letters issued by Guangdong securities regulatory bureau once again pushed Kangmei pharmaceutical to the cusp of the storm.
On April 18, the official website of Guangdong Securities Regulatory Bureau issued three administrative punishment letters. Four insiders related to the reorganization of Kangmei pharmaceutical were fined 500000 yuan each for insider trading. Three of them are current executives Li Jinyun, Xu Wenliu and Pei Jianze from Guangzhou Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Guangzhou Pharmaceutical Group”)P align = “center” source: one of the screenshots of Guangdong Securities Regulatory Bureau
As of the closing on April 22, St Kangmei’s share price closed at 2.72 yuan / share, up 0.74%.
“wishful thinking” is not “satisfactory”
It is reported that the three punished were from Guangzhou Pharmaceutical Group. Among them, Pei ZeJian served as the legal representative of Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guanghua Pharmaceutical Co., Ltd., Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guanghua Health Food Co., Ltd., as well as the senior manager of Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guanghua Pharmaceutical Co., Ltd., Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Mingxing Pharmaceutical Co., Ltd., Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Pharmaceutical Sales Co., Ltd; Xu Wenliu is the chairman of Guangzhou Wanglaoji Health Industry Co., Ltd., and the controlling shareholder of Wanglaoji is still Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Pharmaceutical Group Co., Ltd; Li Jinyun is currently a member of the Party committee and chairman of the trade union of Guangzhou Pharmaceutical Group Co., Ltd.
In addition to the above three people, a fourth person, Yang HaoLing, the son of Li Jinyun, was also involved.
According to the administrative punishment decision of Guangdong securities regulatory bureau, on July 10, 2020, in order to resolve the risks of Kangmei pharmaceutical industry, the relevant departments discussed the selection of enterprises with traditional Chinese medicine production qualification to host Kangmei pharmaceutical industry, and preliminarily determined that the custodian is Guangyao group. On the morning of July 13, Guangzhou Pharmaceutical Group held an enlarged meeting of the Party committee and informed the trusteeship decision. Then, at the special meeting of the trust Kangmei pharmaceutical industry held by Guangzhou Pharmaceutical Group, Li Jinyun, chairman of the trade union of the group, Xu Wenliu and Pei ZeJian attended the meeting.
After receiving the relevant news, the three began to play their “wishful thinking”.
Interestingly, from the evening of July 10 to July 12, 2020, when Li Jinyun communicated with his family that Guangyao group was hosting Kangmei pharmaceutical, his son Yang HaoLing, who lived with him, heard the information. Then on July 12, Yang HaoLing informed Li Jinyun that he was ready to buy Kangmei pharmaceutical shares, and Li Jinyun said he could buy them. On July 13, after Guangyao group informed that it was not allowed to buy and sell “St Kangmei” shares, Li Jinyun asked Yang HaoLing whether to buy “St Kangmei” shares and asked him to sell them.
After the transaction amount of “St Haokang” stock was found to be 13.93 million yuan, the total transaction amount of “St Haokang” securities account was 23.57 million yuan; All were sold on July 14, with a transaction amount of 560200 yuan. After deducting transaction taxes, the transaction loss was 19800 yuan.
Xu Wenliu also bought 500000 shares of St Kangmei on July 13, with a transaction amount of 1.197 million yuan; The trading funds even included loans, which were all sold on July 15, with a turnover of 1.225 million yuan. The above transaction is entrusted by the mobile phone number used by him. After deducting the transaction tax, the transaction profit is 26400 yuan.
Pei ZeJian is no exception. On July 13, it bought and traded 143300 shares of “St Kangmei” shares, with a transaction amount of 344900 yuan. After the sensitive period of inside information, “peizejian” securities account also successively bought 62500 shares of “St Kangmei”, with a purchase transaction amount of 224300 yuan. It was not sold until May 7, 2021 to August 17, 2021. After deducting transaction taxes, the transaction loss was 12300 yuan.
I didn’t expect that stealing chicken can’t erode rice. Only one of the three insider trading cases made a small profit, and the other two suffered a certain loss, which can be described as “drawing water with a bamboo basket in vain”.
Finally, after investigation, Guangdong securities regulatory bureau decided to impose a fine of 500000 yuan on Li Jinyun, Yang HaoLing and Pei Jianze respectively, confiscate 26400 yuan of Xu Wenliu’s illegal income and impose a fine of 500000 yuan.
how is insider trading formed
Previously, Kangmei pharmaceutical had set a record for A-share with a financial fraud of 30 billion. After the CSRC issued a top ticket, Ma Xingtian, chairman of Kangmei pharmaceutical, was sentenced to 12 years’ imprisonment and fined 1.2 million yuan for the crime of manipulating the securities market, illegal disclosure, non disclosure of important information and unit bribery; At the same time, other responsible persons were also sentenced to fixed-term imprisonment and a fine for their participation in relevant securities crimes.
Subsequently, the reorganization of Kangmei Pharmaceutical Co.Ltd(600518) bankruptcy lasted more than one year, and then the intermediate people’s Court of Jieyang City, Guangdong Province ruled that the implementation of Kangmei Pharmaceutical Co.Ltd(600518) bankruptcy reorganization plan was completed and the reorganization procedure was terminated. Public information shows that all debts of Kangmei pharmaceutical have been paid off 100% by means of cash, shares, trust interests and so on. So far, the bankruptcy reorganization of Kangmei pharmaceutical has achieved the goal of reorganization and closed the case as scheduled.
At this time, Guangdong Shennong invested 5.4 billion yuan and jointly invested 6.5 billion yuan with other social capital, holding 29.9% and becoming the largest shareholder of Kangmei pharmaceutical. According to tianyancha data, Guangdong Shennong is composed of state-owned holding enterprises such as Guangyao group, Yuecai industry investment fund, Hengjian assets and Jieyang Jinye.
Under the blessing of Guangyao, St Kangmei began to be popular all the way in the capital market. During this period, he once won the fourth board for four consecutive trading days, and the market value soared from more than 8 billion yuan in February 2021 to 44.9 billion yuan now.
It is understood that Guangzhou Pharmaceutical Group has dispatched a team to fully take over the operation of Kangmei pharmaceutical. At present, the general manager and many deputy general managers of Kangmei pharmaceutical are from Guangzhou Pharmaceutical Group, and there are about 100 Guangzhou Pharmaceutical teams settled in Kangmei. Guangzhou Pharmaceutical Group moved from behind the scenes to the front of the stage and fully intervened in the production and operation of Kangmei pharmaceutical.
In January this year, the chairman of St Kangmei experienced a new term. At present, Lai Zhijian is the director and legal representative of the company. It is reported that Lai Zhijian has successively served as deputy director and director of quality department, marketing director and deputy director of marketing department of Guangzhou chenliji pharmaceutical factory, deputy director of technology and Quality Department of Guangzhou Pharmaceutical Group Co., Ltd. and manager of science and Technology Department of Guangzhou Pharmaceutical Co., Ltd. Now he is the deputy director of quality, director of technology and quality department and director of work safety development department of Guangzhou Pharmaceutical Group Co., Ltd.
So far, St Kangmei has ushered in the official accession of Guangyao group. But now insider trading is exposed, indicating that there may be problems in the internal supervision or management of Guangzhou Pharmaceutical Group.
After the personnel changes of St Kangmei were officially settled, it announced the annual performance forecast for 2021.
According to the latest 2021 performance forecast disclosed by St Kangmei, it turned loss into profit year-on-year in 2021, and the net profit of the company in 2021 is expected to be 5.625 billion yuan to 8.438 billion yuan.
For the reasons for the performance profit, St Kangmei said that it was mainly due to the ruling that the reorganization plan had been implemented and the net income from the relevant reorganization was about 17.5 billion yuan, resulting in a large year-on-year increase in the company’s performance and turning losses into profits.
However, it should be noted that although the revenue turned from loss to profit, the deducted non net profit still remained in the state of loss, ranging from -8.64 billion yuan to -5.76 billion yuan. It is reported that its official annual report will be released on April 29 this year.
